| 3 min read
The novel stem-cell derived retinal organoid provided a new understanding of the disease by showing that damage to retinal pigment epithelium cells is enough to cause neurodegeneration of photoreceptors.
| 4 min read
Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability.
| 4 min read
Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week.
| 6 min read
Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies.
| 3 min read
New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then.News
| 3 min read
First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss.
| 6 min read
As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable.
| 4 min read
FDA approvals and complete responses letters, job cuts, a new FDA commissioner nomination, and more led the news this week.
| 3 min read
The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options.
| 6 min read
A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment.
| 3 min read
Scientists showed that a trio of medications successfully cleared the virus in a rhesus macaque infant model. Clinical testing in human infants could move quickly.
Cancer Research News
A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not.
The Nurix and Roche partnership on bexobrutideg is the latest sign that targeted protein degradation is moving well beyond oncology.
Editor's Pick
Born to differentiate and heal, mesenchymal stem cells carry great potential for treating a wide spectrum of diseases.
In a journey fraught with heartache and persistence, medical research giants paved the way for successful bone marrow transplantation.
Multimedia
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Fujifilm Cellular Dynamics' Nina Bauer on why stem cell-derived assays are becoming essential to drug development, not a replacement for it
